{"id":"W2795058050","doi":"10.1200/jco.2017.76.3656","title":"Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":167,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Bendamustine; Obinutuzumab; Internal medicine; Rituximab; Gastroenterology; Neutropenia; Hazard ratio; Refractory (planetary science); Follicular lymphoma; Surgery; Lymphoma; Chemotherapy; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001355376,0.0005168666,0.001389931,0.0001860314,0.0002143604,0.0006786974,0.0003193933,0.0005839471,0.0005700673],"category_scores_gemma":[0.0011863,0.0002465032,0.001177834,0.0002573539,0.0003447311,0.0004945502,0.000259473,0.0008429178,0.00007879812],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004232851,"about_ca_system_score_gemma":0.0004599816,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005553606,"about_ca_topic_score_gemma":0.001638541,"domain_scores_codex":[0.9995573,0.0002486449,0.00002472954,0.00006643035,0.00003651592,0.00006635734],"domain_scores_gemma":[0.9993215,0.0001979841,0.0001901045,0.000043272,0.00002553245,0.0002216806],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6701981,0.002821024,0.2204241,0.0007630255,0.005562478,0.0003934776,0.0002125611,0.00251239,0.01030964,0.000160047,0.001761285,0.08488185],"study_design_scores_gemma":[0.1796888,0.1665633,0.6294653,0.0001666469,0.01086906,0.0009992619,0.0001626599,0.004085976,0.002700597,0.0005358103,0.004700858,0.00006173155],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.996431,0.002822286,0.00009303198,0.0001319523,0.00004244741,0.00006192788,0.0001191618,0.000009204196,0.0002889456],"genre_scores_gemma":[0.9984937,0.0005393169,0.0001073195,0.0002458158,0.00007465217,0.00005230477,0.0003481296,0.000002678457,0.0001362252],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001389931,"threshold_uncertainty_score":0.007167995,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05563711913773614,"score_gpt":0.380538862532708,"score_spread":0.3249017433949719,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}